Abstract：Objective To investigate the distribution characteristics and clinical features of Burkholderia cepacia infection in children.Methods A retrospective analysis was performed for the clinical data of 16 children with Burkholderia cepacia infection who were hospitalized between June 2012 and September 2017.Results All 16 children with Burkholderia cepacia infection were sporadic cases. A total of 16 strains of Burkholderia cepacia were isolated, among which 8 were detected by sputum culture, 5 were detected by blood culture, 2 were detected by tracheal intubation tip culture, and 1 was detected by lung biopsy culture. Of the 16 children, there were 11 boys and 5 girls, with an age of 5 days to 6 years, and the children aged < 1 year accounted for 69%. As for department distribution, 10 children were in the PICU/NICU and 6 were in the general wards. As for clinical manifestations, one child had disseminated intravascular coagulation, and the other 15 children had pulmonary infection, among who 11 had severe pneumonia (8 of them underwent mechanical ventilation during treatment). As for underlying diseases, 2 had severe congenital heart disease, 4 had primary immunodeficiency, 3 were highly suspected of immunodeficiency or inherited metabolic diseases, 1 had tracheal stenosis, 1 had Kawasaki disease, 1 was a preterm infant with bronchopulmonary dysplasia, 1 had severe cleft lip and palate, and 3 had no definite underlying diseases. Of all the children, 7 also had infections with adenovirus and Mycoplasma. The average length of hospital stay was 20.3 days for all children, and 12 were improved and 4 died after treatment. All 16 strains of Burkholderia cepacia had a drug resistance rate of 100% to amikacin and gentamicin and ≥ 80% to ampicillin/sulbactam and ticarcillin/clavulanic acid, as well as the lowest drug resistance rate o levofloxacin.Conclusions Burkholderia cepacia is an opportunistic pathogen often found in immunocompromised children and can produce drug resistance. The presence or absence of underlying diseases should be considered during anti-infective therapy. The children with Burkholderia cepacia infection often have a poor prognosis, and an understanding of the disease spectrum of Burkholderia cepacia infection helps with clinical diagnosis and treatment.
Clinical and Laboratory Standards Institute. Performance standards for anitimicrobial susceptibility testing[S]. Wayne, PA, 2012:1-184. https://clsi.org/.
[3]
Sousa SA, Ramos CG, Leitão JH, Burkholderia cepacia complex:emerging multihost pathogens equipped with a wide range of virulence factors and determinants[J]. Int J Microbiol, 2011, 2011:607575.
Sousa SA, Ramos CG, Leitão JH. Burkholderia cepacia complex:emerging multihost pathogens equipped with a wide range of virulence factors and determinants[J]. Int J Microbiol, 2011, 2011. pii:607575.
[9]
Porter LA, Goldberg JB. Influence of neutrophil defects on Burkholderia cepacia complex pathogenesis[J]. Front Cell Infect Microbiol, 2011, 1:9.
Allan ND, Beveridge TJ. Gentamicin delivery to Burkholderia cepacia group Ⅲa strains via membrane vesicles from Pseudomonas aeruginosa PAO1[J]. Antimicrob Agents Chemother, 2003, 47(9):2962-2965.
